Back to Search
ISRAT JAHAN GAZI D.O
D.O
Family Medicine Physician
NPI: 1477934461IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
R6194(TX)
Education
NEW YORK COLLEGE OF OSTEO MEDICINE OF NEW YORK INSTITUTE OF TECHNOLOGY
Class of 2015
Research & Publications (20)
Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia.
PMID 19682687·Atherosclerosis·2010
8-other
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.
PMID 19535817·J Lipid Res·2009
3-trial
Kidney function and estimated vascular risk in patients with primary dyslipidemia.
PMID 19572030·Open Cardiovasc Med J·2009
8-other
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.
PMID 18956219·Lipids·2009
8-other
Orlistat-associated adverse effects and drug interactions: a critical review.
PMID 18095746·Drug Saf·2008
6-review
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
PMID 17459096·Diabetes Obes Metab·2008
4-observational
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics.
PMID 17474139·NMR Biomed·2008
8-other
Increased plasma visfatin levels in subjects with the metabolic syndrome.
PMID 18173555·Eur J Clin Invest·2008
4-observational
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia.
PMID 17519084·Curr Med Res Opin·2007
3-trial
Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
PMID 17692154·Curr Med Res Opin·2007
8-other
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
PMID 16911813·Atherosclerosis·2007
4-observational
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.
PMID 17150019·Expert Opin Biol Ther·2007
6-review
The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia.
PMID 17164494·Clin Appl Thromb Hemost·2007
8-other
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles.
PMID 17426995·Lipids·2007
8-other
LDL-cholesterol calculation formulas in patients with or without the metabolic syndrome.
PMID 17045352·Int J Cardiol·2007
2-rct
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
PMID 17656665·Arterioscler Thromb Vasc Biol·2007
3-trial
Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease.
PMID 17877651·Int J Clin Pract·2007
4-observational
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp.
PMID 17065709·Diabetes Care·2006
8-other
Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome.
PMID 18370738·Metab Syndr Relat Disord·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 4 locations total
- Address
- 500 N Kobayashi Ste F
Webster, TX 77598 - Phone
- (281) 724-1860
Locations (4)
Quick Facts
- NPI
- 1477934461
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 4
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile